Kura Oncology, Inc.
NASDAQ:KURABiotechnology
+$0.07 today
- Market cap
- $674.39M
- Beta
- 0.36
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$3.32
Volume 2.46M
Average 1.66M
KURA Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Kura Oncology, Inc.NASDAQ: KURA
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses grows, but more slowly than its trailing trend
Q1 FY2026 operating expenses of $96.46M rose 22.4% year over year, behind the +42.1% change in trailing-twelve-month operating expenses. Sequentially, it fell 6.9% from the prior quarter. Over 3 fiscal years it compounded at +38.4% a year.
Context
- Operating expenses amounted to 549.9% of revenue in FY2025, up 91.3 pp from a year earlier.
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +22.4% toward the trailing-twelve-month pace of +42.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 371.06M USD
- Year-over-year change
- +50.2%
- 4-year CAGR
- +29.7%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 371.06M | +50.2% |
| FY2024 | 2024-12-31 | 247.08M | +49.8% |
| FY2023 | 2023-12-31 | 164.96M | +17.9% |
| FY2022 | 2022-12-31 | 139.87M | +6.6% |
| FY2021 | 2021-12-31 | 131.26M | — |
Operating Expenses vs competitors
How KURA compares with its peers on the latest reported figures
- KURA's LTM Mar 2026 operating expenses of $385.56M is the 2nd highest of the 11 companies compared; the peer median is $152.48M.
- Its year-over-year change of +42.1% is the 5th highest of 11, against a peer median of +19.2%.
- Operating expenses amounts to 538.2% of revenue for KURA, versus a peer median of 126.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $436.26M | +12.8% | +42.4% | 200.9% | |
| LTM Mar 2026 | $385.56M | +42.1% | +38.4% | 538.2% | |
| LTM Aug 2026 | $317.52M | +142.5% | +109.8% | 45.2% | |
| LTM Mar 2026 | $212.38M | +50.5% | +37.4% | 428.3% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $168.68M | +90.5% | +3360.1% | — |
| LTM Mar 2026 | $155.37M | +12.5% | -5.0% | 51.8% | |
| LTM Mar 2026 | $149.59M | +2.2% | +15.6% | — | |
| LTM Mar 2026 | $142.77M | +25.7% | +31.1% | — | |
| LTM Jun 2025 | $73.46M | +0.2% | -20.0% | 12.2% | |
| LTM Sep 2026 | $39.45M | +46.4% | -12.9% | — | |
| LTM Mar 2026 | $36.37M | -15.3% | +7.1% | 6928.2% | |
| Peer median (excluding KURA) | $152.48M | +19.2% | +23.4% | 126.4% | |
Competitors are the stored peer set for KURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 53.88M | 67.48M |
| Cost of Revenue | 0 | 0 | 849K | 0 | 57K |
| Gross Profit | 0 | 0 | (849K) | 53.88M | 67.43M |
| Gross Margin | — | — | — | 100.0% | 99.9% |
| Research & Development | 84.72M | 92.81M | 115.24M | 169.97M | 251.07M |
| Selling, General & Admin | 46.54M | 47.05M | 50.57M | 77.11M | 119.98M |
| Operating Expenses | 131.26M | 139.87M | 164.96M | 247.08M | 371.06M |
| Depreciation & Amortization | 558K | 759K | 849K | 848K | 1.03M |
| EBITDA | (129.49M) | (134.85M) | (150.23M) | (169.5M) | (275.83M) |
| EBITDA Margin | — | — | — | -314.6% | -408.7% |
| Operating Income | (131.26M) | (139.87M) | (165.8M) | (193.2M) | (303.63M) |
| Operating Margin | — | — | — | -358.5% | -449.9% |
| Interest Income | 1.21M | 4.25M | 14.72M | 22.85M | 26.77M |
| Interest Expense | 414K | 229K | 1.55M | 1.62M | 1.51M |
| Other Income / Expenses | 792K | 4.03M | 13.17M | 21.23M | 25.26M |
| Income Before Tax | (130.47M) | (135.84M) | (152.63M) | (171.97M) | (278.37M) |
| Pre-Tax Margin | — | — | — | -319.1% | -412.5% |
| Income Tax Expense | 0 | 0 | 0 | 2.02M | 297K |
| Net Income | (130.47M) | (135.84M) | (152.63M) | (173.98M) | (278.67M) |
| Net Margin | — | — | — | -322.9% | -412.9% |
| EPS (Basic) | (1.97) | (2.03) | (2.08) | (2.02) | (3.18) |
| EPS (Diluted) | (1.97) | (2.03) | (2.08) | (2.02) | (3.18) |
| Weighted Avg Shares | 66.35M | 66.99M | 73.23M | 86.16M | 87.68M |
| Weighted Avg Shares (Diluted) | 66.35M | 66.99M | 73.23M | 86.16M | 87.68M |
Kura Oncology, Inc.
NASDAQ:KURA
Intrinsic Alpha fair value
Locked
Current Price
$7.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.